About This Trial

Individualized neoantigen therapy in combination with Keytruda for high-risk melanoma patients post-surgery.

Primary Endpoints

  • Recurrence-free survival
  • Overall survival

Latest Update

February 2026

Phase 2b results showed 44% reduction in recurrence/death risk vs Keytruda alone. FDA granted Breakthrough Therapy designation.

Lead Investigators

DJ
Dr. Jeffrey WeberDeputy Director, Perlmutter Cancer Center, NYU